Document:

Addendum #1 to Share Exchange Agreement

 

LEGACY VENTURES INTERNATIONAL INC.

 

 

ADDENDUM #1 TO 

SHARE EXCHANGE AGREEMENT

 

 

This Addendum #1 (the “Addendum,”), effective as of November 20, 2015 (the “Effective Date”) is attached to and forms part of the Share Exchange Agreement (the “Agreement”) dated as September 30, 2015  (the “Addendum #1”) by and among Legacy Ventures International Inc., a corporation organized under the laws of the State of Nevada (the “Acquiror”), Rehan Saeed (the “Acquiror Principal Shareholder”), RM Fresh Brands Inc., a corporation organized under the laws of the Province of Ontario, Canada (the “Acquiree”), Ron Patel and Mirwan Ferris (collectively, the “Acquiree Shareholders,” and individually an “Acquiree Shareholder”).  Each of the Acquiror, Acquiror Principal Shareholder, Acquiree and Acquiree Shareholders are referred to herein individually as a “Party” and collectively as the “Parties.”

Capitalized terms not defined herein shall have the same meaning as set forth in the Agreement. 

 

The parties agree that wherever there is any conflict among this Addendum and the Agreement, the provisions of this Addendum will control and the Agreement will be construed accordingly.

 

Notwithstanding any terms in the Agreement to the contrary, the Company and the Purchaser agree as follows:    

 

Under the “Recital” section and Section 2.2 Share Cancellation of the Agreement, the amount of shares cancelled by the Acquiror Principal Shareholder shall be amended from 35,800,000 to read 25,800,000.  Simultaneously, the Acquiror Principal Shareholder agrees to transfer an aggregate of 10,000,000 shares of Company’s common stock in accordance with the schedule and to the individuals identified on Exhibit A attached hereto and incorporated by reference. All other terms and conditions of the Agreement shall remain intact.

 

 

IN WITNESS WHEREOF, the Parties have caused their respective signature pages to this Addendum to be duly executed as of the date first written above.

 

IN WITNESS WHEREOF, the undersigned have caused this Agreement to be executed as of the date first above written.

[Signatures follow on next page]

 

 

 

 

 

 

1902630.1

 

IN WITNESS WHEREOF, the undersigned have caused this Addendum to be executed as of the date first above written.

	ACQUIROR:

	 

	Legacy Ventures International Inc.

	 
 

	By:
	/s/ Evan Clifford____________________

	Name:
	Evan Clifford

	Title:
	President and Chief Executive Officer

	 

	By:       /s/ Rehan Saeed_____________________

	Name:  Rehan Saeed

	Title: Chief Financial Officer and Former President and Chief Executive Officer
 

	ACQUIROR PRINCIPAL SHAREHOLDER:

	 
 
            /s/ Rehan Saeed______________________

	Name: Rehan Saeed

 

[Signatures continue on next page]

 

2 

1902630.1

 

 

IN WITNESS WHEREOF, the undersigned have caused this Addendum to be executed as of the date first above written.

	ACQUIREE

RM Fresh Brands Inc.:

	 

	By:
	/s/ Ron Patel

	Name:
	Ron Patel

	Title:
	President

 

[Signatures continue on next page]

 

 

 

 

3 

1902630.1

 

IN WITNESS WHEREOF, the undersigned have caused this Addendum to be executed as of the date first above written.

	ACQUIREE SHAREHOLDERS
 

	 
 
/s/Ron Patel

	Name: Ron Patel
 
 

	 
 
/s/ Mirwan Ferris

	Name: Mirwan Ferris

 

 

 

 

 

 

 

4 

1902630.1

 

 

Exhibit A

	Name & Address
	# of Shares

	Evan Clifford
 
	2,000,000

	2155798 Ontario Ltd.
 
	2,000,000

	Saeed Uz Zafar Khan                                
 
	2,000,000

	Victor Altomare
 
	2,000,000

	Christopher Crupi
 
	1,000,000

	Tracey Logan
 
	1,000,000

 

5 

1902630.1Addendum #1 to Share Cancellation Agreement

LEGACY VENTURES INTERNATIONAL INC.

 

 

ADDENDUM #1 TO 

SHARE CANCELLATION AGREEMENT

 

 

This Addendum #1 (the “Addendum,”), effective as of November 20, 2015 (the “Effective Date”) is attached to and forms part of the Share Cancellation Agreement (the “Agreement”) dated as of September 30, 2015  (the “Addendum #1”) between LEGACY VENTURES INTERNATIONAL INC. (the “Company’), a Nevada corporation, and Rahan Saeed, individually, ( the “Shareholder”).  Company and Shareholder are hereinafter individually and jointly referred to as “Party” and/or “Parties.

Capitalized terms not defined herein shall have the same meaning as set forth in the Agreement. 

 

The Parties agree that wherever there is any conflict among this Addendum and the Agreement, the provisions of this Addendum will control and the Agreement will be construed accordingly.

 

Notwithstanding any terms in the Agreement to the contrary, the Company and the Shareholder agree as follows:    

 

Under the “Recital” section of the Agreement, the amount of shares cancelled by the  Shareholder shall be amended from 35,800,000 to read 25,800,000.  Simultaneously, the Shareholder agrees to transfer an aggregate of 10,000,000 shares of Company’s common stock in accordance with the schedule and to the individuals identified on Exhibit A attached hereto and incorporated by reference.  All other terms and conditions of the Agreement shall remain intact.

 

 

IN WITNESS WHEREOF, the Parties have caused their respective signature pages to this Addendum to be duly executed as of the date first written above.

 

IN WITNESS WHEREOF, the undersigned have caused this Agreement to be executed as of the date first above written.

(signature page follows on the next page)

 

 

 

 

 

 

 

 

 

 

1902637.1

IN WITNESS WHEREOF, the Parties hereto have executed this Addendum as of the date first above written.  

 

Legacy Ventures International Inc.

 

By:/s/ Evan Clifford_________________

Name: Evan Clifford 

Title: President & Chief Executive Officer

 

Legacy Ventures International Inc.

 

By:/s/ Rehan Saeed__________________

Name: Rehan Saeed 

Title: Chief Financial Officer & Former President

 

 

By:/s/Rehan Saeed___________________

Rehan Saeed, Individually 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

2 

1902637.1

Exhibit A

	Name & Address
	# of Shares

	Evan Clifford
 
	2,000,000

	2155798 Ontario Ltd.
 
	2,000,000

	Saeed Uz Zafar Khan                                
 
	2,000,000

	Victor Altomare
 
	2,000,000

	Christopher Crupi
 
	1,000,000

	Tracey Logan
 
	1,000,000

 

 

 

 

 

 

 

 

3 

1902637.1Lightbridge Corporation - Exhibit 10.3 - Filed by newsfilecorp.com

Exhibit 10.3

AMENDMENT

TO THE

LIGHTBRIDGE CORPORATION

2015 EQUITY INCENTIVE PLAN

THIS AMENDMENT is made as of November 20, 2015, by Lightbridge
Corporation, a Nevada corporation (the “Company”).

WHEREAS, the Company has heretofore established and maintains
the Lightbridge Corporation 2015 Equity Incentive Plan (the “Plan”);

WHEREAS, pursuant to Section 13 of the Plan, the Board of
Directors has the authority to amend the Plan; and

WHEREAS, after determining that it is in the best interests of
the Company and its stockholders, the Compensation Committee of the Board of
Directors approved, and the Board of Directors ratified and approved, an
amendment to Section 4.3 of the Plan to increase the individual limit for awards
thereunder.

NOW, THEREFORE, BE IT RESOLVED, that the Plan is hereby amended
by restating Section 4.3 of the Plan in its entirety, effective immediately as
follows:

“4.3 Subject to
adjustment in accordance with Section 11, no Participant shall be granted,
during any one (1) year period, Options to purchase Common Stock and Stock
Appreciation Rights with respect to more than one million five hundred thousand
(1,500,000) shares of Common Stock in the aggregate or any other Awards with
respect to more than one million five hundred thousand (1,500,000) shares of
Common Stock in the aggregate. If an Award is to be settled in cash, the number
of shares of Common Stock on which the Award is based shall count toward the
individual share limit set forth in this Section 4.”Exhibit

Exhibit 10.1
Waiver Letter

November 23, 2015

Thomas K Equels, President
HEMISPHERX BIOPHARMA, INC.
One Penn Center
1617 JFK Boulevard
Philadelphia, Pennsylvania 19103 

Dear Mr. Equels,

For the purpose of assisting Hemispherx Biopharma, Inc. (the “Company”) in preserving cash and to help the Company to ensure its commercialization goals for Ampligen and Alferon-N, effective November 23, 2015 I waive my rights under Section 3(c)(ii) of the Amended and Restated Employment Agreement between the Company and me entered into as of December 6, 2011 to any future payment of any incentive bonus related to the sale of the Company’s stock or other securities by, or on behalf of, the Company pursuant to the Equity Distribution Agreement between the Company and Maxim Group LLC, dated July 23, 2012, as amended (the “Maxim Agreement”), or any similar or successor ATM equity distribution agreement. I make this waiver for the sole and exclusive purpose of assisting the Company in reaching its commercialization goals and do so without making any admissions concerning the scope of my rights under Section 3(c)(ii) of the Employment Agreement or the propriety of any consideration I previously have received thereunder.  

/s/ Willaim A. Carter
Dr. William A. Carter
Waiver Acknowledged:
HEMISPHERX BIOPHARMA, INC.

By:   /s/ Thomas K. Equels    
        Thomas K. Equels, CFO

cc: Peter Rodino, William Mitchell, Iraj E Kiani

Corporate Headquarters
One Penn Center, 1617 JFK Blvd, Suite 500, Philadelphia, PA 19103                t: 215-988-0080       f: 215-988-1739
Manufacturing  
783 Jersey Ave, New Brunswick, NJ 08901                          www.hemispherx.net                   t: 732-249-3250       f: 732-249-6895
Shipping:  5 Jules Lane, New Brunswick, NJ 08901Exhibit

Exhibit 10.2
Waiver Letter
November 23, 2015

William A. Carter, M.D., CEO
HEMISPHERX BIOPHARMA, INC.
One Penn Center
1617 JFK Boulevard
Philadelphia, Pennsylvania 19103 

Dear Dr. Carter,

For the purpose of assisting Hemispherx Biopharma, Inc. (the “Company”) in preserving cash and to help the Company to ensure its commercialization goals for Ampligen and Alferon-N, effective November 23, 2015 I waive my rights under Section 3(c)(ii) of the Amended and Restated Employment Agreement between the Company and me entered into as of December 6, 2011 to any future payment of any incentive bonus related to the sale of the Company’s stock or other securities by, or on behalf of, the Company pursuant to the Equity Distribution Agreement between the Company and Maxim Group LLC, dated July 23, 2012, as amended (the “Maxim Agreement”), or any similar or successor ATM equity distribution agreement. I make this waiver for the sole and exclusive purpose of assisting the Company in reaching its commercialization goals and do so without making any admissions concerning the scope of my rights under Section 3(c)(ii) of the Employment Agreement or the propriety of any consideration I previously have received thereunder.  

                                                                                         /s/ Thomas K. Equels
Thomas K Equels
Waiver Acknowledged:
HEMISPHERX BIOPHARMA, INC.

By:   /s/Willaim A. Carter   
         William A Carter, CEO

cc: Peter Rodino, William Mitchell, Iraj E. Kiani

Corporate Headquarters
One Penn Center, 1617 JFK Blvd, Suite 500, Philadelphia, PA 19103                t: 215-988-0080       f: 215-988-1739
Manufacturing  
783 Jersey Ave, New Brunswick, NJ 08901                          www.hemispherx.net                   t: 732-249-3250       f: 732-249-6895
Shipping:  5 Jules Lane, New Brunswick, NJ 08901

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00251-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00251-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00251-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00251-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00251-of-00352.parquet"}]]